Concepts (224)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 42 | 2022 | 3272 | 2.410 |
Why?
|
| Thyroid Neoplasms | 14 | 2021 | 469 | 2.180 |
Why?
|
| Carcinoma, Ductal, Breast | 11 | 2019 | 166 | 1.750 |
Why?
|
| Mastectomy | 19 | 2022 | 271 | 1.660 |
Why?
|
| Lymph Nodes | 13 | 2018 | 560 | 1.530 |
Why?
|
| Sentinel Lymph Node Biopsy | 10 | 2018 | 88 | 1.510 |
Why?
|
| Thyroidectomy | 11 | 2021 | 181 | 1.500 |
Why?
|
| Lymph Node Excision | 10 | 2018 | 238 | 1.480 |
Why?
|
| Carcinoma, Lobular | 10 | 2019 | 83 | 1.450 |
Why?
|
| Carcinoma, Papillary | 8 | 2020 | 165 | 1.310 |
Why?
|
| Mastectomy, Segmental | 8 | 2017 | 115 | 1.300 |
Why?
|
| Adrenocortical Carcinoma | 4 | 2022 | 15 | 1.150 |
Why?
|
| Adrenal Cortex Neoplasms | 4 | 2022 | 21 | 1.150 |
Why?
|
| Iodine Radioisotopes | 6 | 2021 | 145 | 1.140 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 5 | 2016 | 133 | 1.060 |
Why?
|
| Carcinoma | 5 | 2017 | 440 | 0.960 |
Why?
|
| Lymphatic Metastasis | 16 | 2020 | 520 | 0.850 |
Why?
|
| Parathyroidectomy | 3 | 2020 | 87 | 0.820 |
Why?
|
| Hyperparathyroidism, Primary | 3 | 2020 | 51 | 0.720 |
Why?
|
| Databases, Factual | 18 | 2020 | 1094 | 0.700 |
Why?
|
| Neoplasm Staging | 20 | 2021 | 2080 | 0.680 |
Why?
|
| Radiopharmaceuticals | 4 | 2016 | 217 | 0.660 |
Why?
|
| Axilla | 13 | 2018 | 109 | 0.610 |
Why?
|
| Hypercalcemia | 1 | 2018 | 60 | 0.550 |
Why?
|
| Middle Aged | 57 | 2021 | 29427 | 0.550 |
Why?
|
| Radiotherapy, Adjuvant | 9 | 2021 | 323 | 0.540 |
Why?
|
| Female | 68 | 2022 | 51535 | 0.510 |
Why?
|
| Aged | 47 | 2021 | 21758 | 0.510 |
Why?
|
| Guideline Adherence | 2 | 2017 | 250 | 0.500 |
Why?
|
| Thyroid Gland | 6 | 2021 | 297 | 0.500 |
Why?
|
| Pancreatic Neoplasms | 6 | 2018 | 769 | 0.490 |
Why?
|
| Neoadjuvant Therapy | 5 | 2019 | 478 | 0.430 |
Why?
|
| Retrospective Studies | 27 | 2022 | 10972 | 0.420 |
Why?
|
| Humans | 75 | 2022 | 98076 | 0.420 |
Why?
|
| Prognosis | 21 | 2019 | 4116 | 0.410 |
Why?
|
| Aged, 80 and over | 20 | 2021 | 7389 | 0.400 |
Why?
|
| Surgeons | 3 | 2022 | 325 | 0.350 |
Why?
|
| Carcinoma, Pancreatic Ductal | 3 | 2018 | 156 | 0.340 |
Why?
|
| Adult | 33 | 2021 | 29538 | 0.340 |
Why?
|
| Combined Modality Therapy | 7 | 2022 | 1751 | 0.330 |
Why?
|
| United States | 21 | 2022 | 8196 | 0.310 |
Why?
|
| Receptors, Estrogen | 5 | 2019 | 428 | 0.300 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2015 | 659 | 0.300 |
Why?
|
| Adenocarcinoma | 4 | 2016 | 1211 | 0.290 |
Why?
|
| Survival Rate | 13 | 2020 | 2041 | 0.290 |
Why?
|
| Follow-Up Studies | 16 | 2021 | 4025 | 0.290 |
Why?
|
| Logistic Models | 6 | 2020 | 1275 | 0.280 |
Why?
|
| Neck Dissection | 2 | 2021 | 67 | 0.280 |
Why?
|
| Pancreaticoduodenectomy | 3 | 2017 | 99 | 0.270 |
Why?
|
| Practice Guidelines as Topic | 5 | 2019 | 1109 | 0.270 |
Why?
|
| Nipples | 5 | 2022 | 40 | 0.270 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2021 | 1535 | 0.250 |
Why?
|
| Chemotherapy, Adjuvant | 8 | 2019 | 525 | 0.250 |
Why?
|
| Technetium Tc 99m Sulfur Colloid | 3 | 2004 | 10 | 0.240 |
Why?
|
| Ergonomics | 3 | 2022 | 26 | 0.240 |
Why?
|
| Minimally Invasive Surgical Procedures | 2 | 2019 | 309 | 0.230 |
Why?
|
| Male | 27 | 2021 | 47075 | 0.230 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2017 | 159 | 0.230 |
Why?
|
| Age Factors | 8 | 2021 | 1962 | 0.220 |
Why?
|
| Treatment Outcome | 10 | 2021 | 9711 | 0.210 |
Why?
|
| Melanoma | 1 | 2009 | 524 | 0.210 |
Why?
|
| Neoplasm Invasiveness | 6 | 2020 | 582 | 0.210 |
Why?
|
| Length of Stay | 4 | 2022 | 878 | 0.200 |
Why?
|
| Patient Selection | 3 | 2013 | 726 | 0.200 |
Why?
|
| Skin Neoplasms | 1 | 2009 | 638 | 0.200 |
Why?
|
| Biopsy, Needle | 2 | 2003 | 226 | 0.200 |
Why?
|
| Biomarkers, Tumor | 4 | 2019 | 1764 | 0.190 |
Why?
|
| Brachytherapy | 2 | 2014 | 139 | 0.180 |
Why?
|
| Risk Factors | 7 | 2021 | 6232 | 0.180 |
Why?
|
| Mastectomy, Subcutaneous | 1 | 2022 | 8 | 0.180 |
Why?
|
| Surgical Oncology | 2 | 2020 | 34 | 0.180 |
Why?
|
| Precancerous Conditions | 1 | 2003 | 218 | 0.170 |
Why?
|
| Hospitals, High-Volume | 1 | 2022 | 47 | 0.170 |
Why?
|
| Receptors, Progesterone | 2 | 2019 | 207 | 0.170 |
Why?
|
| Breast | 1 | 2003 | 315 | 0.170 |
Why?
|
| Adrenalectomy | 2 | 2018 | 41 | 0.170 |
Why?
|
| Proportional Hazards Models | 7 | 2017 | 922 | 0.160 |
Why?
|
| Time Factors | 5 | 2021 | 5567 | 0.160 |
Why?
|
| Mammaplasty | 1 | 2022 | 125 | 0.160 |
Why?
|
| Survival Analysis | 4 | 2017 | 1527 | 0.160 |
Why?
|
| Thyroid Epithelial Cells | 1 | 2020 | 9 | 0.160 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2017 | 1012 | 0.160 |
Why?
|
| Adenoma, Oxyphilic | 1 | 2020 | 37 | 0.150 |
Why?
|
| Medical Overuse | 1 | 2019 | 32 | 0.150 |
Why?
|
| Organ Sparing Treatments | 1 | 2019 | 52 | 0.150 |
Why?
|
| Pancreatectomy | 2 | 2017 | 201 | 0.150 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2019 | 2658 | 0.140 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2021 | 903 | 0.140 |
Why?
|
| Thoracic Wall | 1 | 2018 | 26 | 0.130 |
Why?
|
| Adenocarcinoma, Follicular | 1 | 2018 | 60 | 0.130 |
Why?
|
| Biopsy | 2 | 2017 | 1224 | 0.130 |
Why?
|
| Mesenteric Veins | 1 | 2017 | 38 | 0.130 |
Why?
|
| Chromosome Aberrations | 1 | 2018 | 352 | 0.130 |
Why?
|
| Radiation Oncology | 1 | 2019 | 130 | 0.130 |
Why?
|
| Prophylactic Mastectomy | 1 | 2016 | 13 | 0.120 |
Why?
|
| Vascular Surgical Procedures | 1 | 2017 | 166 | 0.120 |
Why?
|
| Neoplasm Grading | 5 | 2016 | 422 | 0.120 |
Why?
|
| Hepatectomy | 1 | 2017 | 203 | 0.120 |
Why?
|
| Laparoscopy | 3 | 2018 | 791 | 0.120 |
Why?
|
| Young Adult | 8 | 2021 | 7507 | 0.120 |
Why?
|
| Quality Improvement | 1 | 2020 | 520 | 0.110 |
Why?
|
| Chromatin | 1 | 2018 | 454 | 0.110 |
Why?
|
| Risk | 1 | 2016 | 660 | 0.110 |
Why?
|
| Parathyroid Neoplasms | 1 | 2015 | 61 | 0.110 |
Why?
|
| Societies, Medical | 1 | 2019 | 682 | 0.110 |
Why?
|
| Decision Support Techniques | 1 | 2016 | 194 | 0.110 |
Why?
|
| Mammography | 3 | 2017 | 504 | 0.110 |
Why?
|
| Quality of Health Care | 1 | 2017 | 391 | 0.100 |
Why?
|
| Epigenesis, Genetic | 1 | 2018 | 588 | 0.100 |
Why?
|
| Propensity Score | 3 | 2021 | 213 | 0.100 |
Why?
|
| Prospective Studies | 8 | 2021 | 4823 | 0.100 |
Why?
|
| Genes, BRCA2 | 1 | 2014 | 162 | 0.100 |
Why?
|
| Genes, BRCA1 | 1 | 2014 | 191 | 0.100 |
Why?
|
| Neoplasms, Second Primary | 1 | 2015 | 244 | 0.100 |
Why?
|
| Disease-Free Survival | 2 | 2011 | 1193 | 0.100 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2016 | 336 | 0.100 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2017 | 450 | 0.100 |
Why?
|
| Thyroid Diseases | 1 | 2013 | 108 | 0.090 |
Why?
|
| Patient Satisfaction | 1 | 2016 | 511 | 0.090 |
Why?
|
| Time-to-Treatment | 1 | 2014 | 157 | 0.090 |
Why?
|
| Patient Education as Topic | 1 | 2016 | 417 | 0.090 |
Why?
|
| Liver | 1 | 2017 | 1231 | 0.090 |
Why?
|
| Estrogen Receptor alpha | 1 | 2013 | 159 | 0.090 |
Why?
|
| Contraindications | 1 | 2012 | 66 | 0.090 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2013 | 200 | 0.090 |
Why?
|
| Multivariate Analysis | 4 | 2017 | 1009 | 0.090 |
Why?
|
| Adolescent | 7 | 2021 | 10079 | 0.080 |
Why?
|
| Workload | 2 | 2022 | 130 | 0.080 |
Why?
|
| Liver Neoplasms | 1 | 2017 | 831 | 0.080 |
Why?
|
| Operating Rooms | 2 | 2022 | 144 | 0.080 |
Why?
|
| Liver Transplantation | 1 | 2017 | 1235 | 0.080 |
Why?
|
| SEER Program | 3 | 2015 | 243 | 0.070 |
Why?
|
| Predictive Value of Tests | 3 | 2018 | 1782 | 0.070 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2009 | 52 | 0.070 |
Why?
|
| Radionuclide Imaging | 4 | 2004 | 183 | 0.070 |
Why?
|
| Interferon-alpha | 1 | 2009 | 191 | 0.070 |
Why?
|
| Margins of Excision | 2 | 2018 | 49 | 0.070 |
Why?
|
| Immunologic Factors | 1 | 2009 | 179 | 0.060 |
Why?
|
| Cancer Vaccines | 1 | 2009 | 168 | 0.060 |
Why?
|
| Tumor Burden | 2 | 2021 | 333 | 0.060 |
Why?
|
| Cohort Studies | 3 | 2021 | 3212 | 0.060 |
Why?
|
| Pilot Projects | 3 | 2019 | 977 | 0.060 |
Why?
|
| Chromosome Mapping | 1 | 2009 | 1061 | 0.060 |
Why?
|
| Reoperation | 2 | 2021 | 727 | 0.060 |
Why?
|
| Sequence Analysis, DNA | 1 | 2009 | 911 | 0.060 |
Why?
|
| Early Diagnosis | 1 | 2006 | 141 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2017 | 3605 | 0.050 |
Why?
|
| Genome, Human | 1 | 2009 | 832 | 0.050 |
Why?
|
| Hyperplasia | 1 | 2003 | 148 | 0.050 |
Why?
|
| Patient Readmission | 2 | 2017 | 424 | 0.050 |
Why?
|
| Radiotherapy Dosage | 2 | 2014 | 479 | 0.050 |
Why?
|
| Medically Uninsured | 1 | 2022 | 72 | 0.040 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2003 | 121 | 0.040 |
Why?
|
| Sensitivity and Specificity | 3 | 2018 | 1945 | 0.040 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2021 | 50 | 0.040 |
Why?
|
| Algorithms | 1 | 2009 | 2002 | 0.040 |
Why?
|
| Insurance Coverage | 1 | 2022 | 152 | 0.040 |
Why?
|
| Mass Screening | 1 | 2006 | 745 | 0.040 |
Why?
|
| Datasets as Topic | 1 | 2020 | 84 | 0.040 |
Why?
|
| Hernia, Inguinal | 1 | 2020 | 75 | 0.040 |
Why?
|
| Herniorrhaphy | 1 | 2020 | 95 | 0.040 |
Why?
|
| Neoplasm Micrometastasis | 1 | 2018 | 7 | 0.030 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2018 | 108 | 0.030 |
Why?
|
| Conversion to Open Surgery | 1 | 2018 | 11 | 0.030 |
Why?
|
| Thyroid Nodule | 1 | 2018 | 65 | 0.030 |
Why?
|
| Clinical Decision-Making | 1 | 2020 | 305 | 0.030 |
Why?
|
| Hematoxylin | 1 | 1997 | 9 | 0.030 |
Why?
|
| Eosine Yellowish-(YS) | 1 | 1997 | 14 | 0.030 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2018 | 41 | 0.030 |
Why?
|
| Keratins | 1 | 1997 | 62 | 0.030 |
Why?
|
| Coloring Agents | 1 | 1997 | 70 | 0.030 |
Why?
|
| Postoperative Hemorrhage | 1 | 2017 | 55 | 0.030 |
Why?
|
| Nucleic Acid Conformation | 1 | 2018 | 348 | 0.030 |
Why?
|
| Operative Time | 1 | 2017 | 175 | 0.030 |
Why?
|
| Blood Loss, Surgical | 1 | 2017 | 140 | 0.030 |
Why?
|
| Ultrasonography, Mammary | 1 | 2017 | 86 | 0.030 |
Why?
|
| Blood Transfusion | 1 | 2017 | 180 | 0.030 |
Why?
|
| Shock, Septic | 1 | 2017 | 145 | 0.030 |
Why?
|
| Healthcare Disparities | 1 | 2022 | 539 | 0.030 |
Why?
|
| Medical Oncology | 1 | 2020 | 421 | 0.030 |
Why?
|
| Prevalence | 1 | 2020 | 1384 | 0.030 |
Why?
|
| Selection Bias | 1 | 2014 | 37 | 0.030 |
Why?
|
| Self Report | 1 | 2016 | 355 | 0.030 |
Why?
|
| Chemoradiotherapy | 1 | 2017 | 337 | 0.030 |
Why?
|
| Decision Making | 1 | 2019 | 686 | 0.030 |
Why?
|
| Hospitals, Public | 1 | 2013 | 15 | 0.030 |
Why?
|
| Neoplasm, Residual | 1 | 2015 | 206 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2019 | 1565 | 0.020 |
Why?
|
| Age Distribution | 1 | 2013 | 208 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 1997 | 1815 | 0.020 |
Why?
|
| Heterozygote | 1 | 2014 | 390 | 0.020 |
Why?
|
| Insurance, Health | 1 | 2014 | 186 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2017 | 1089 | 0.020 |
Why?
|
| Urban Population | 1 | 2013 | 246 | 0.020 |
Why?
|
| Sex Factors | 1 | 2015 | 1138 | 0.020 |
Why?
|
| Illinois | 1 | 2013 | 522 | 0.020 |
Why?
|
| Registries | 1 | 2017 | 1122 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2017 | 2013 | 0.020 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2000 | 1173 | 0.020 |
Why?
|
| Referral and Consultation | 1 | 2014 | 418 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2017 | 2783 | 0.020 |
Why?
|
| Hospitals | 1 | 2013 | 336 | 0.020 |
Why?
|
| General Surgery | 1 | 2013 | 262 | 0.020 |
Why?
|
| Expressed Sequence Tags | 1 | 2009 | 34 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2017 | 2585 | 0.020 |
Why?
|
| Health Services Accessibility | 1 | 2014 | 532 | 0.020 |
Why?
|
| Postmenopause | 1 | 2009 | 109 | 0.020 |
Why?
|
| Lung Neoplasms | 1 | 2000 | 2457 | 0.020 |
Why?
|
| Quality of Life | 1 | 2016 | 1895 | 0.020 |
Why?
|
| Palpation | 1 | 2006 | 19 | 0.010 |
Why?
|
| Community Health Services | 1 | 2006 | 81 | 0.010 |
Why?
|
| Mutation | 1 | 2014 | 4392 | 0.010 |
Why?
|
| Ranitidine | 1 | 2000 | 8 | 0.010 |
Why?
|
| Intraoperative Period | 1 | 2000 | 91 | 0.010 |
Why?
|
| Premedication | 1 | 2000 | 57 | 0.010 |
Why?
|
| Cyclophosphamide | 1 | 2000 | 284 | 0.010 |
Why?
|
| Doxorubicin | 1 | 2000 | 285 | 0.010 |
Why?
|
| Physical Examination | 1 | 2000 | 149 | 0.010 |
Why?
|
| Fluorouracil | 1 | 2000 | 541 | 0.010 |
Why?
|
| Dexamethasone | 1 | 2000 | 318 | 0.010 |
Why?
|
| Paclitaxel | 1 | 2000 | 483 | 0.010 |
Why?
|
| Remission Induction | 1 | 2000 | 754 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2000 | 801 | 0.010 |
Why?
|
| Ultrasonography | 1 | 2000 | 720 | 0.010 |
Why?
|